Most recent by Megan Baldwin, PhD
VIDEO: Sozinibercept in ‘last push’ of phase 3 clinical development
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Megan Baldwin, PhD, of Opthea, shares an update on sozinibercept, a VEGF-C/D inhibitor for the treatment of neovascular age-related macular degeneration.
VIDEO: Sozinibercept in ‘last push’ of phase 3 clinical development
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Megan Baldwin, PhD, of Opthea, shares an update on sozinibercept, a VEGF-C/D inhibitor for the treatment of neovascular age-related macular degeneration.
VIDEO: Opthea presents update on sozinibercept for wet AMD
SEATTLE — In this Healio Video Perspective from OIS Retina, Megan Baldwin, PhD, provides an update on OPT-302, now called sozinibercept, for the treatment of neovascular age-related macular degeneration.
VIDEO: Opthea CEO discusses updates on OPT-302 for treatment of wet AMD
CHICAGO — In this video from Eyecelerator@AAO, Opthea CEO Megan Baldwin, PhD, discusses updates for OPT-302, a therapy targeting a new mechanism of action for the treatment of wet age-related macular degeneration.